02:53 PM EDT, 09/30/2025 (MT Newswires) -- Aurinia Pharmaceuticals ( AUPH ) issued a statement Tuesday in response to a retracted LinkedIn post from a US Food and Drug Administration official referencing its drug Lupkynis, saying it continues to stand behind the drug's benefit/risk profile.

Lupkynis received FDA approval in January 2021 for adult patients with active lupus nephritis, supported by the 52-week Aurora 1 trial, Aurinia said.

In April 2024, the FDA also approved a supplementary new drug application for long-term use based on results from Aurora 2, which showed sustained efficacy over three years with safety comparable to the earlier trial, the company said.

Shares were up 1.3% in recent afternoon trading.

Price: 11.20, Change: +0.14, Percent Change: +1.27